Clinical genomic tests increasingly utilize a next generation sequencing (NGS) platform due in part to the high fidelity of variant calls, yet rare errors are still possible. In hereditary cancer screening (HCS), failure to correct such errors could have serious consequences for patients, who may follow an unwarranted screening or surgical-management path. It has been suggested that routine orthogonal confirmation via Sanger sequencing is required to verify NGS results, especially low-confidence positives with depressed allele balance (<30% of the alternate allele).
INTRODUCTION
Hereditary cancer screening (HCS) has well established clinical validity and clinical utility: it ascribes increased cancer risk to particular germline variants [1] [2] [3] , and the presence of these variants often alters patient management 4, 5 . As a result, accurate variant detection is critical. Though multiple HCS validation studies demonstrate exemplary analytical sensitivity and specificity 6, 7 , even rare analytical errors-false positives or false negatives-could grossly misrepresent an individual patient's risk of cancer and, consequently, have grave clinical consequences.
Though NGS is now mature and widely used for HCS 8, 9 , in its nascency NGS was particularly susceptible to false positives, generally resulting from low coverage and high rates of both random errors and systematic errors on early instruments [10] [11] [12] [13] . For instance, NGS data alone could not resolve the genotype at a site with 4x depth and 25% allele balance (i.e., one read with an alternate base and three reads with reference bases): either a sequencer error occurred in a patient homozygous for the reference allele, or the allele balance was depressed in a heterozygous patient due to the discreteness of few observations.
Variant-calling ambiguities in early NGS data prompted medical societies to suggest that variants identified on clinical panels required confirmation 14, 15 . With low-depth, high-error NGS data, no level of algorithmic sophistication or added manual scrutiny could resolve certain genotypes; therefore, confirmatory evidence needed to come from an orthogonal technology, typically Sanger sequencing 16 . However, advances in NGS technology over time (e.g., lower
per-base error rates and hybrid-capture protocols that yield high depth in regions of interest)
have substantially increased achievable variant-calling confidence 12 , calling into question the recommendation for routine confirmation of NGS results. Indeed, whether Sanger sequencing confirmation of NGS data should be routine is a contentious topic in the clinical genomics field:
some studies argue that it is critical 17, 18 ; others suggest that it is largely unnecessary 19, 20 , and yet another claims that it can actually increase the odds of a clinical lab returning false results 21 .
In a concordance analysis of NGS and Sanger sequencing data from >20,000 HCS patients, Mu and 
METHODS

Institutional Review Board approval
The study protocol was reviewed and designated as exempt by Western Institutional
Review Board (WIRB). Patient information was de-identified according to the Health Insurance Portability and Accountability Act Privacy Rule. An informed consent waiver was approved by WIRB.
Patient cohort
The study includes variant-calling results from 15,080 de-identified patients screened 
Screen description
The Reliant Cancer Screen workflow begins with assembly of a sequencing batch ( Figure 1A ). DNA from patients' blood or saliva samples is extracted and prepared for NGS via barcoded adapter ligation and PCR. A 96-well batch contains clinical samples, cell-line samples that act as genotype controls (e.g., NA12878), and no-template wells to detect contamination.
During the sequencing step ( Figure 1B ), hybridization-capture probes enrich for targeted regions of interest (20nt padded exons and known-deleterious, deep-intronic sites). In this study, we considered variants in the following genes:
SMAD4
, STK11 , TP53 , and VHL . We perform paired-end NGS, described previously elsewhere 6 .
After sequencing, variant calling commences in the bioinformatics pipeline ( Figure 1C ).
SNVs and indels are identified with the Genome Analysis Toolkit 22 , Freebayes 23 , and custom genotyping software for representing complex haplotypes spanning clustered calls. Though their quality assessment is not addressed here, copy-number variants (CNVs) are found via a custom calling algorithm 6 and undergo MaCRO confirmation as well. Prior to rendering in MaCRO, the bioinformatics pipeline computes various metrics at the sample level (e.g., GC bias, fraction covered) and call level (e.g., depth, strand bias and allele balance).
Manual Call Review Optimization (MaCRO)
The MaCRO software interface is a custom database-backed web application implemented in the Django framework leveraging Postgres optimizations. It loads calls and their associated metrics from the bioinformatics pipeline, as well as pathogenicity interpretations (from tools like SNPEFF 24 , from external resources like ClinVar 25 and dbSNP 26 , and from our internal database). Because it is software driven, the review workflow is strictly controlled and, therefore, robust, auditable, and reproducible from batch to batch and from operator to operator over time.
The first step in the workflow includes evaluation of batch-level metrics (e.g., number of samples passing QC criteria, average sample depth) and confirmation that both control-sample genotypes and QC metrics matched expectation. If metrics or control calls are unexpected, the reviewer can fail the batch to queue it for retesting. Next, the operator reviews sample-level metrics, which include pre-sequencing (e.g., DNA concentration) and post-sequencing (e.g., base quality, depth variance, contamination, etc.) quality-control data. Sample with metrics outside of validated boundaries are queued for retesting.
Upon passing of the batch, controls, and qualified samples, a single secure webpage loads and segments all calls from the entire batch into separate tables for SNVs/indels ( Figure   1D ) and CNVs. To balance the needs for expedient and meticulous review, the interface displays each call's information via tiered panels of increasing detail, the last of which depicts raw NGS reads ( Figure 1D ; the page also links to a genome browser for graphical representation of reads). MaCRO confirmation of variant calls is performed by a single operator, but any call overrides (i.e., where manual inspection reverses the algorithmically determined genotype) can be flagged and annotated directly within the MaCRO software, prompting review by a second operator to minimize the possibility of human error. Tabs stratify calls based on the variants' confidence (i.e., call vs. no-call) and clinical-interpretation class (i.e., known deleterious, likely deleterious, VUS, likely benign, and known benign). Every variant in a patient's ordered panel that is deleterious or a VUS is reviewed. Known-and likely-benign variant calls do not undergo routine review as part of the MaCRO SOP, but they are loaded into the interface for ready access. Finally, the MaCRO software compiles data from multiple runs of a single sample (when applicable) to ensure within-sample concordance prior to reporting.
A MaCRO operator in our laboratory must be licensed as a Clinical Genetic Molecular Biologist Scientist in California and have a minimum of 2 years of experience performing NGS and/or reviewing NGS results.
For this study, variant calls and their metrics, raw data links (e.g., BAM files), and timestamps were queried from our production databases, de-identified, and then analyzed.
Sanger confirmation
For Sanger sequencing confirmation of a putative positive call at a given site, the region flanking the site was PCR amplified using DNA extracted from a clinical sample of interest. This amplified genomic DNA was the substrate for bidirectional Sanger sequencing reactions (BigDye, ThermoFisher), which used custom and manually designed sequencing primers that were ~100nt upstream or downstream of the site. Sanger sequencing traces were acquired on a 3730 instrument (ThermoFisher) and interpreted in 4Peaks.
RESULTS
Our assessment of MaCRO confirmation for all potentially reportable positive calls began with a compilation of each call's allele balance and read depth, as these two factors are key drivers of call confidence (Figure 2A 
MaCRO confirmation resolves ambiguous positive calls
MaCRO confirmation applied to NGS variant calls in the ambiguous zone revealed a mixture of positive, negative, and mosaic calls ( Figure 2B ). Though MaCRO was applied to all putative NGS positive calls in Figure 2B , we performed retrospective Sanger sequencing only on variants in the ambiguous zone (described below). We found that allele balance and depth alone cannot resolve ambiguous variant calls, but manual review of the NGS data was sufficient to yield a confident call without a requirement for Sanger confirmation.
Ambiguous calls were resolved by inspection of the raw NGS data during MaCRO confirmation. Figure 3 shows two variants from the study that are representative of others in the ambiguous zone: one is a confirmed heterozygous deletion with depressed allele balance ( Figure 3A-C) , and the other is a site with spuriously elevated allele balance at which the patient is confirmed to be homozygous for the reference allele ( Figure 3D-F) .
The 40nt deletion in Figure 3A had low allele balance due to an artifact of NGS-read alignment. Whereas the alignment software registered 12% of reads as harboring the deletion (i.e., those with purple lines in Figure 3A ), the remaining reads were a mixture of reference-matching sequences and other reads that had a short series of SNVs near their termini ( Figure 3A ). Closer scrutiny of the pileup revealed that start and end points of the SNV series colocalized with the breakpoints of the deletion. Indeed, as shown in Figure 3B , the pastel-shaded soft-clipped reads were a perfect match with the 40nt deletion, but they were not initially aligned as such in the bioinformatics pipeline because they did not have enough sequence flanking the deletion. This expected limitation of the alignment software was overcome during MaCRO confirmation, enabling the reviewer to identify that the true allele balance exceeded 12% and was indicative of the patient being heterozygous for a deleterious variant. Of the MaCRO-confirmed positive samples in the ambiguous zone ( Figure 2B ), 82%
were indels (Supplemental Table S1 ), and this example was the largest observed, which suggests efficacy of MaCRO across a broad range of indel sizes.
Conspicuous PCR errors were another common artifact easily detectable during MaCRO-confirmation; one such error is illustrated in Figure 3D . In the pileup, the only evidence for heterozygosity was the T nucleotide, present in 8% of reads but always in reads that were from the same strand and at the same position. Using our hybrid-capture technology, a real heterozygous site should have the alternate base interspersed among reads on both strands and with a range of endpoints (suggestive of being from different molecules in the genomic library). Further, because multiple capture probes interrogate each position and the capture probe for a particular fragment can often be inferred from paired-end data, MaCRO confirmation can also require that a legitimate variant be sampled via multiple probes. After suppressing the clearly spurious reads in the pileup ( Figure 3E ), the sample was MaCRO confirmed to be negative.
Perfect concordance between MaCRO confirmation and Sanger confirmation
We evaluated the efficacy of MaCRO confirmation by performing a retrospective Sanger sequencing analysis on variants in the ambiguous zone. All ambiguous variants (N=1,719) were concentrated at 42 sites (see Discussion). For all such sites, at least one sample with an ambiguous positive NGS call was Sanger sequenced. The genotypes elucidated via Sanger confirmation and MaCRO confirmation were perfectly concordant (shown comprehensively in Figure 4 and anecdotally in Figure 3C ,F), indicating that Sanger sequencing offered no additional clinical benefit beyond the evaluation by MaCRO.
Feasibility of MaCRO confirmation in a high-throughput clinical lab
As genomic panels grow and screening becomes more widespread, it is important for confirmation methodologies to be efficient and scalable. We measured the time required for a single operator to apply MaCRO confirmation to a batch of samples ( Figure 5A ). Specifically, we Sanger sequencing is one such way for a laboratory to implement a confirmation workflow.
However, it is not the only confirmation method, and here we have described and validated MaCRO confirmation as an effective alternative.
In a large patient cohort, MaCRO confirmation resolved genotypes among ambiguous low-allele-balance calls, identifying them as positive, negative, or mosaic with the same accuracy as Sanger sequencing. The 1,719 ambiguous calls we observed were concentrated among only 42 sites. This redundancy of many calls at a given site reinforces the idea that ambiguous calls are often systematic technical artifacts at the molecular level (e.g., elevated
rate of PCR errors in homopolymers) or the algorithmic level (e.g., misalignment of large indels, alignment challenges in difficult-to-sequence regions like homopolymers, or spurious variants near the termini of reads). MaCRO was able to reveal these technical artifacts because the NGS chemistry enables parameterization of reference and alternate reads on three dimensions: the read strand, the fragment start position, and the likely capture probe for a fragment (inferred from paired-end data). Therefore, a stringent set of conditions could be applied to qualify a site as being heterozygous; it must have reference and alternate reads on both strands, at diverse positions, and from different capture probes. Conversely, spurious NGS calls could be identified by failing to show evidence of reference and alternate reads on any dimension (e.g., all alternate reads coming from one strand, one position, or one capture probe). Importantly, the high specificity conferred via MaCRO confirmation guards against false positives, which means that the bioinformatics pipeline can accordingly be optimized for sensitivity to minimize false negatives as well.
We observed that confirmation via MaCRO and Sanger sequencing have comparable analytical performance in variant detection, but there are nontrivial differences in efficiency, scalability, affordability, and turnaround time. Each screen-positive sample receiving Sanger confirmation was estimated to incur one week of additional lab processing and a $240 cost 19 . By contrast, with an average MaCRO review time of 15 minutes for a batch of 90 samples, and assuming $100/hr compensation for a MaCRO operator, the average marginal review time and cost per sample are 10 seconds and $0.28, respectively. As a strategy to prevent ballooning the cost and turnaround time of HCS, several studies have suggested confining use of Sanger confirmation only to ambiguous calls and/or indels 17, 20, 27 . But, MaCRO confirmation by comparison is so much more efficient that it can plausibly be applied to all reportable calls in a clinical setting, which is important because we observed MaCRO-confirmed negatives with allele balance >30% ( Figure 2B ). The increased scope, speed, and affordability of the MaCRO workflow relative to Sanger confirmation should increase accessibility of HCS testing and reduce overall turnaround time of the test, while simultaneously maintaining the quality of patient reports.
Although we performed Sanger confirmation on all ambiguous variant sites with allele balance <30%, a limitation of our study is that we did not perform Sanger sequencing to verify MaCRO-confirmation performance for variant calls with >30% allele balance. However, though we cannot disprove the possibility of a false positive among these confident calls, several studies have performed exhaustive Sanger sequencing on confident variants and found no false positives [17] [18] [19] 21 . Another limitation is that, for individual sites at which multiple samples had the same variant (e.g., we found 15 variants in a POLE intron at position chr12:133256063), we often performed Sanger sequencing on one to five samples. Nevertheless, based on the perfect concordance observed between the two approaches at a variety of sites, we expect high performance of MaCRO in samples not further interrogated with Sanger sequencing. Finally, because MaCRO is human-operated, it is accordingly susceptible to human-operator error. We attempt to limit such error via engineering controls, e.g., by the interface requiring that any override to a call during MaCRO confirmation be certified by more than one MaCRO operator.
However, a miscall could result if the initial reviewer did not appropriately interpret the data to conclude that a call should be overturned. Importantly, susceptibility to human error is not unique to MaCRO confirmation; it can equally impair interpretation of Sanger sequencing results.
We have demonstrated that manual review of NGS data can be feasibly executed in a clinical setting and is highly accurate, yet two recent studies 17, 18 Without such an accounting, it is not clear that Sanger sequencing in particular is a necessity.
Together, these publications underscore our assertion that confirmation of NGS-detected variants is strictly required, but the confirmatory method can take different forms.
MaCRO does not strictly supersede Sanger sequencing in our HCS testing. Sanger sequencing is used extensively during development and validation 6 to characterize assay performance and identify potentially problematic regions. In production, however, the validated The cumulative-density plot shows the fraction of batches for which MaCRO confirmation occurred within the number of hours indicated (x-axis) following completion of NGS and bioinformatics processing.
